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2Abstract
Objective: Asthma and abdominal aortic aneurysms (AAA) both involve inflammation. Patients 
with asthma have an increased risk of developing AAA or experiencing aortic rupture. This 
study tests the development of one disease on the progression of the other. 
Approach and Results: Ovalbumin sensitization and challenge in mice led to the development 
of allergic lung inflammation (ALI). Subcutaneous infusion of angiotensin II (Ang-II) into mice 
produced AAA. Simultaneous production of ALI in AAA mice doubled abdominal aortic 
diameter and increased macrophage and mast cell content, arterial media smooth muscle cell 
(SMC) loss, cell proliferation, and angiogenesis in AAA lesions. ALI also increased plasma IgE, 
reduced plasma IL5, and increased bronchioalveolar total inflammatory cell and eosinophil 
accumulation. Intraperitoneal administration of an anti-IgE antibody suppressed AAA lesion 
formation and reduced lesion inflammation, plasma IgE, and bronchioalveolar inflammation. 
Pre-establishment of ALI also increased AAA lesion size and lesion accumulation of 
macrophage, mast cell, and media SMC loss, increased plasma IgE, reduced plasma IL5, IL13, 
and TGF-, and increased bronchioalveolar inflammation. Consequent production of ALI also 
doubled lesion size of pre-established AAA and increased lesion mast cell and T cell 
accumulation, media SMC loss, lesion cell proliferation and apoptosis, plasma IgE, and 
bronchioalveolar inflammation. In peri-aortic CaCl2 injury-induced AAA in mice, production of 
ALI also increased AAA formation, lesion inflammation, plasma IgE, and bronchioalveolar 
inflammatory cell accumulation.
Conclusion: This study suggests a pathologic link between airway allergic disease and AAA. 
Production of one disease aggravates the progression of the other.
Abbreviations
AAA: abdominal aortic aneurysms; ALI: allergic lung inflammation; Ang-II: angiotensin II; T 
helper 1 and T helper 2: TH1 and TH2; BALF: bronchioalveolar lavage fluid; OVA: ovalbumin; 
H&E: hematoxylin and eosin.
INTRODUCTION
Asthma and abdominal aortic aneurysms (AAA) are chronic inflammatory diseases that 
share many biochemical and pathological similarities. Patients or animals with asthma or AAA 
have elevated plasma IgE levels.
1,2
In asthmatic patients, bronchial and alveolar accumulation of 
eosinophils, mast cells, macrophages, and lymphocytes indicates an important signature of the 
disease.
3
Similarly, in human and experimental AAA lesions, accumulation of macrophages, T 
cells, mast cells, and neutrophils determines the initiation and progression of this aortic disease 
and pathology.
4
Our recent studies demonstrated an important role of IgE in mouse experimental 
AAA development. In apolipoprotein E-deficient (Apoe
–/–
) mice, the absence of IgE receptor 
FcR1 protected these mice from angiotensin II (Ang-II)-induced AAA. Anti-IgE antibody 
treatment also mitigated AAA progression.
2
These prior studies suggest an interaction between 
asthma and AAA.
3The Viborg Vascular screening trial of 18,749 men from Denmark demonstrated a 45% 
AAA risk increase in patients with a record of an asthmatic medication prescription. Although 
smoking is an important risk factor of human and mouse AAA,
5-7
adjustment of cigarette 
smoking did not attenuate asthma-associated risk of AAA (unpublished observation). The Danish 
National Registry of Patients population of 15,942 men with AAA revealed a 30% to 100% 
aortic rupture risk increase in patients with an asthma diagnosis or experience with anti-
asthmatic treatments (unpublished observation). These clinical observations suggest that asthma 
increases the risk of AAA incidence as well as aortic rupture. This current study tested this 
hypothesis in Apoe
–/–
mice. The infusion of Ang-II helps produce AAA in Apoe
–/–
mice.
8,9
Ovalbumin sensitization and challenge produce allergic lung inflammation (ALI) in mice.
10,11
We produced ALI and AAA simultaneously or sequentially in Apoe
–/–
mice to test whether the 
development of ALI at the same time as, before, or after AAA production affects AAA 
development.
MATERIALS AND METHODS
Materials and Methods are available in the online-only Data Supplement.
RESULTS 
Allergic lung inflammation promotes experimental AAA in mice
We first concurrently produced ALI together with Ang-II (1,000 ng kg
−1
min
−1
) mediated 
AAA in Apoe
–/–
mice (Figure 1A). Compared with mock (saline)-sensitized mice, OVA-
sensitized mice exhibited significantly enlarged maximal aortic diameters (4.34±0.46 mm vs.
2.31±0.21 mm, P=0.001) (Figure 1B) and aortic cross-section AAA lesion areas (P=0.036), 
increased lesion Mac-2
+
macrophage-positive areas (P=0.044) and mast cell (P=0.011) content 
(Figure 1C), increased media SMC loss (P<0.001), lesion cell proliferation (P=0.047), and 
microvascularization (P=0.004) (Figure 1D). Fisher’s exact test did not show a significant 
difference in post-Ang-II infusion mortality rate between the two groups (Table I in the online-
only Data Supplement, left). OVA-sensitized AAA mice showed significantly higher plasma IgE 
(P=0.004) but reduced plasma IL5 (P=0.044) concentrations (Figure 1E). BALF total 
inflammatory cells and leukocyte differential counts confirmed production of ALI. OVA-
sensitized AAA mice showed significantly higher total BALF inflammatory cell counts 
(P=0.031), eosinophil (P=0.001) (Figure 1F), and lymphocyte (P=0.015) percentages than mock-
sensitized AAA mice, with concurrent reduction of macrophage percentages (P<0.001). In AAA 
mice with concurrent ALI, elevated AAA lesion sizes may associate with their high plasma IgE 
levels and high lesion macrophage and mast cell contents. IgE-mediated activation of 
macrophages and mast cells may contribute to enhanced AAA development in these mice
(Figure 1B/1C).
2
Allergic inflammation did not significantly affect mouse body weight, blood 
pressure, plasma lipid contents, or any tested BALF cytokines and chemokines, including IFN-, 
TNF-, eotaxin, MCP-1, IL4, IL5, IL13, and TGF- (Table I in the online-only Data 
Supplement, left). Asthmatic patients or ALI mice often have increased plasma IL5 and IL13.
12-
14
Human AAA lesions and those from Ang-II-infused Apoe
–/–
mice also revealed elevated IL5 
expression.
15,16
Anti-IL5 antibody reduced Ang-II-induced AAA in Apoe
–/–
mice,
16
suggesting a 
4pro-aneurysmogenic role of IL5. Co-development of ALI and AAA may have increased plasma 
IL5 and IL13. Why these mice showed reduced plasma IL5 remains unknown (Figure 1E). 
Contrast to the IL5 expression in AAA lesions, plasma IL5 did not differ between AAA and 
AAA-free patients.
17
In Apoe
–/–
mice, IL5 expression in Ang-II-induced AAA lesions at 28 days 
after Ang-II infusion did not differ from those of normal mice.
16
Therefore, multiple factors may 
impact the production of IL5 or IL13 in mice with ALI and AAA.
The second group of mice (Figure 2A) first underwent production of ALI, then AAA 
induction with Ang-II (1,000 ng kg
−1
min
−1
). OVA-sensitized mice again developed significantly 
larger aortic diameters (3.07±0.32 mm vs. 1.95±0.24 mm, P=0.006) (Figure 2B) and cross-
section lesion areas (P=0.033) when compared to mock-sensitized mice (Table I in the online-
only Data Supplement, right), although aortic rupture post-Ang-II infusion did not differ between 
the groups. OVA-sensitized mice exhibited higher levels of lesion Mac-2
+
macrophage-positive 
areas (P=0.007), mast cells (P<0.001), and medial SMC loss (P=0.010) than mock-sensitized 
mice (Figure 2C/2D). Compared with mock-sensitized mice, OVA-sensitized mice had 
significantly higher plasma IgE levels (P=0.001), but lower anti-inflammatory plasma IL5 
(P=0.002), IL13 (P=0.019), and TGF- (P=0.050) (Figure 2E). OVA-sensitized AAA mice had 
significantly higher numbers of BALF total inflammatory cells and percentages of BALF 
eosinophils (P=0.026) (Figure 2F) and lymphocytes (P=0.002), but reduced percentages of 
macrophages (P=0.018), affirming production of ALI (Figure 2F). OVA-sensitized AAA mice 
showed an increase in post-AAA diastolic blood pressures (P=0.035) and reduction of BALF 
IL13 levels (P=0.023), but the other variables measured, including plasma lipoproteins and 
BALF proteins, did not differ significantly from those of mock-sensitized mice (Table I in the 
online-only Data Supplement, right).
Allergic lung inflammation exacerbates pre-established AAA in mice
We also tested whether induction of ALI after AAA production exacerbated pre-
established AAA. A group of 8~10-week-old male Apoe
–/–
mice did not undergo AAA induction, 
but started OVA or mock sensitization on day 29 as controls (Figure 3A). Control mice without 
AAA did not exhibit significant changes in abdominal aortic diameter (1.000±0.054 mm vs.
1.026±0.046 mm, P=0.727), cross-section areas, or any other arterial wall pathological variables 
between OVA- and mock-sensitized mice, except collagen content, which was lower in OVA-
sensitized mice when compared to mock-sensitized mice (P=0.020). OVA-sensitized mice also 
had lower plasma total cholesterol (P=0.017) and triglyceride (P=0.040) levels than mock-
sensitized mice (Table II in the online-only Data Supplement, left). As anticipated, OVA-
sensitized Apoe
–/–
mice had increased plasma IgE (P=0.006), IFN- (P=0.022), and IL5 
concentrations (P=0.033) (Figure 3B).
10,11
OVA-sensitized mice showed higher BALF levels of 
total inflammatory cells (P=0.002) and percentages of eosinophils (P<0.001) (Figure 3C) and 
lymphocytes (P<0.001) than mock-sensitized mice, whereas OVA-sensitized mice revealed 
reduced macrophage percentages (P<0.001). OVA-sensitized mice had higher BALF 
concentrations of IgE (P=0.011), TNF- (P=0.020), MCP-1 (P=0.004), IL5 (P=0.004), and IL13 
(P=0.029) than mock-sensitized mice (Table II in the online-only Data Supplement, left).
Next, we produced AAA in 8~10-week-old male Apoe
–/–
mice. Then, at 29 days post-
Ang-II infusion, animals underwent OVA or mock immunization to produce airway allergic 
inflammation (Figure 3D). In Apoe
–/–
mice that had pre-established AAA, development of ALI
did not affect body weight, blood pressure, plasma lipoprotein, BALF cytokines, or blood 
chemokine concentrations (Table II in the online-only Data Supplement, right). In sharp contrast, 
5OVA-sensitized mice had significantly larger aortic diameters (2.71±0.42 mm vs. 1.49±0.14 mm,
P=0.020) (Figure 3E), cross-section AAA lesion areas (P=0.041), lesion mast cells (P=0.012), 
CD4
+
T cells (P=0.014), CD8
+
T cells (P=0.010), medial SMC loss (P<0.001), lesional Ki67
+
cells (P=0.038), and apoptotic cells (P=0.038) (Figure 3F/3G). Plasma from OVA-sensitized 
AAA mice had increased TNF- and reduced TGF- concentrations. Plasma IgE levels were 
also higher in OVA-sensitized mice than in mock-sensitized mice, although such a difference did 
not reach statistical significance (0.49±0.09 µg/mL vs. 0.35±0.07 µg/mL, P=0.309) (Figure 3H). 
IgE action on mast cells and T cells contributes to AAA formation.
2
Action of IgE on elevated 
lesion mast cells and T cells (Figure 3F) may contribute to enhanced AAA in OVA-sensitized 
mice (Figure 3E). While plasma IgE concentrations with Ang-II-induced AAA in Apoe
–/–
mice 
increased when compared to control mice,
2
OVA-sensitized mice (without AAA) had similar 
plasma IgE concentrations as Ang-II infusion-induced AAA mice (without asthma) (0.40±0.07 
µg/mL vs. 0.35±0.07 µg/mL, P=0.726). The OVA-sensitized mice had significantly increased 
total inflammatory cells and eosinophils (Figure 3H) in BALF, affirming the production of 
allergic inflammation in OVA-sensitized mice. Two sets of data in Table II in the online-only 
Data Supplement provide detailed analyses of the AAA lesions and allergic inflammation from 
mice presented in Figure 3A and 3D.
Pre-established AAA aggravates OVA-sensitized mouse airway allergic responses
The comparison of data from OVA-sensitized mice with and without AAA determined 
whether pre-established AAA influenced the development of ALI (Figure 3A/3D). Relative to 
the absence of pre-existing AAA, OVA-sensitized AAA mice showed significantly increased 
plasma concentrations of IFN- (P=0.011), eotaxin (P=0.015), IL4 (P=0.005), IL5 (P=0.048), 
and TGF- (P=0.049). OVA-sensitized AAA mice also had enlarged aortic diameters 
(2.712±0.418 mm vs. 1.000±0.054 mm, P=0.003), increased aortic cross-section lesion areas, 
and higher lesion macrophages, mast cells, CD4
+
and CD8
+
T cells, MHC-II-positive areas, 
media SMC loss, elastin fragmentation, lesion cell proliferation and apoptosis, and 
microvascularization relative to OVA-sensitized mice without AAA (Table III in the online-only 
Data Supplement, left). BALF cell analysis showed that pre-established AAA significantly 
increased BALF total inflammatory cells (P=0.006), macrophages (P=0.004), lymphocytes 
(P=0.003), and eosinophils (P=0.030) in OVA-sensitized mice. Pre-establishment of AAA did 
not affect most tested cytokines and chemokines in BALF. Mice with pre-established AAA 
(Table III in the online-only Data Supplement, left) only showed reduced IL5 (P=0.009) and 
TGF- (P=0.011). Pre-established AAA in mock-sensitized mice increased aortic diameters 
(1.488±0.138 mm vs. 1.026±0.046 mm, P=0.009), lesion areas (P=0.011), lesion macrophages 
(P<0.001), mast cells (P<0.001), CD4
+
T cells (P<0.001), CD8
+
T cells (P<0.001), the 
inflammatory marker MHC-II (P=0.009), medial SMC loss (P<0.001), elastin fragmentation 
grade (P<0.001), cell proliferation (P<0.001), apoptosis (P<0.001), and microvascularization 
(P<0.001) (Table III in the online-only Data Supplement, right). Pre-established AAA in mock-
sensitized mice also increased plasma IgE (P=0.007), IFN- (P=0.001), TNF- (P=0.004), 
eotaxin (P=0.003), and TGF- (P=0.018), as well as lymphocytes (P=0.032). Plasma IL4 
(P=0.047) and IL13 (P=0.012) fell, but BALF total inflammatory cells, macrophages, 
eosinophils, and neutrophils did not change significantly. Pre-established AAA also increased 
BALF IgE (P=0.005), TNF- (P=0.001), eotaxin (P=0.006), and IL13 (P=0.028), and reduced 
BALF TGF- (P=0.004) in mock-sensitized mice (Table III in the online-only Data Supplement, 
right), suggesting that AAA augments concentrations of lung inflammatory mediators.
6Airway allergic inflammation promotes peri-aortic CaCl2 injury-induced AAA
The introduction of ALI to peri-aortic CaCl2 injury-induced AAA in wild-type mice 
helped test whether the pro-aneurysmogenic activity of ALI applies to other experimental AAA. 
Production of ALI greatly increased AAA lesion size and cross-sectional lesion area, compared 
to those of saline-sensitized mice (Figure 4A), with significant increase of lesion macrophages, 
mast cells, media SMC loss, and lesion microvessel contents (Figure 4B-4E). BALF total 
inflammatory cell accumulation was also higher in AAA mice with ALI than in mice without 
ALI (Figure 4F). ELISA detected significantly higher plasma IgE levels in mice with both AAA 
and ALI than in mice with AAA but sensitized with saline, but plasma IL5 and IL13 levels did 
not differ significantly between the two groups of mice (Figure 4G). Such insignificant 
difference in plasma IL5 and IL13 levels may associate with AAA production of the two groups 
of mice.
13-16
Anti-IgE antibody mitigates AAA in mice with airway allergic inflammation
Mice with concurrent development of ALI and AAA (Figure 1A) showed significant 
increase of AAA lesion size (Figure 1B), lesion inflammatory cell accumulation (Figure 1C), and 
plasma IgE levels (Figure 1E). ALI-induced plasma IgE increase may contribute to increased 
AAA sizes in mice with concurrent ALI and AAA. The administration of anti-IgE monoclonal 
antibody to Ang-II-infused mice sensitized with OVA or saline tested this hypothesis. Two doses 
of intraperitoneal injection of anti-IgE antibody greatly reduced plasma IgE levels from both 
groups of mice (Figure 4H). In ALI mice, the significant suppression of enlarged AAA sizes and 
cross-section lesion areas occurred after anti-IgE antibody treatment (Figure 4I), as well as lesion 
macrophage contents (Figure 4J). As anticipated, the suppression of elevated inflammatory cell
accumulation in BALF from ALI mice occurred after anti-IgE antibody treatment (Figure 4K), as 
previously reported.
18,19
DISCUSSION
This study established an association between ALI and AAA in Ang-II-induced AAA 
mice. Mice with ALI from an inhaled allergen showed significantly enhanced AAA progression, 
before, during, or after AAA induction, although data did not show significant differences in 
post-Ang-II infusion superarenal aortic rupture between mice with or without ALI. These 
observations agree with our preliminary observation from the Viborg Vascular screening trial of 
619 AAA patients from 18,749 men. The lack of knowledge in interactions between allergy and 
AAA may be the cause of incomplete screening information specific for asthma among the AAA 
populations. The use of anti-asthmatic prescription records helped indicate asthma among this 
screening population. Patients with such a prescription experienced a 45% higher AAA risk than 
those without (OR=1.450, 95% C.I.: 1.096-1.918, P<0.01) (unpublished observation). 
Allergic asthma
20-22
and AAA
23-25
involve the T helper cell 2 (TH2) cytokines IL4, IL5, 
and IL13 and the TH1 cytokines IFN- and TNF- in both humans and animals. Increased 
allergic airway responses augment BALF IgE and cytokines/chemokines (TNF-, eotaxin, MCP-
1, IL5, IL13).
10,11
OVA sensitization- and challenge-induced production of these cytokines in 
mice with ALI appeared to be aneurysmogenic in these mice. In this study, allergen sensitization 
and challenge did not change most of the tested BALF cytokines and chemokines regardless 
whether AIL and AAA were produced sequentially or at the same time, suggesting common 
7mechanisms for the development of type 2 inflammation in the lung and aorta during 
aneurysmogenesis. 
Both allergen and Ang-II infusion induced similar levels of plasma and BALF IgE. We 
reported previously that Ang-II infusion increased plasma IgE to 0.3 to 0.4 µg/mL.
2
This study 
yielded similar results. While mice without AAA or airway allergic inflammation had plasma 
IgE concentrations around 0.05 µg/mL, mice with AAA alone without allergic inflammation had 
plasma IgE levels of 0.35 to 0.42 µg/mL (Table I and II in the online-only Data Supplement). 
These levels resemble those of mice with allergic inflammation alone without AAA that also had 
plasma IgE levels at 0.40 µg/mL (Table II in the online-only Data Supplement). Plasma IgE 
concentrations increased approximately two-fold to 0.93 and 0.92 µg/mL in mice with both ALI
and AAA (Table I in the online-only Data Supplement). These data suggest an additive influence 
on plasma IgE levels of ALI and AAA. We recently reported that IgE participates in 
experimental AAA by activating mast cells, macrophages, and CD4
+
and CD8
+
T cells.
2
These 
cells all localize in the aneurysmal mouse aorta. IgE also activates vascular SMCs and 
endothelial cells, promoting apoptosis of these vascular cells,
26
which contribute to aortic 
aneurysm formation and rupture.
27-29
Mice that receive an anti-IgE antibody (e.g. Xolair) 
biweekly have full protection from AAA formation.
2
Here we tested further a role of IgE in 
AAA. In mice with concurrent ALI and AAA, two doses of biweekly intraperitoneal injection of 
rat anti-mouse IgE monoclonal antibody depleted plasma IgE and significantly reduced AAA 
lesion size and macrophage accumulation (Figure 4H-4I). Therefore, the increased plasma IgE 
(Figure 2E/3E/4H and Table I in the online-only Data Supplement) may link ALI to AAA 
pathogenesis, although additional mechanisms may also contribute to the activity of ALI in 
inducing AAA, which requires further investigation. Anti-IgE antibody (e.g. Xolair) may serve 
as a novel regimen for human AAA, although an appropriate dose and formulation may be 
required for an optimized efficacy. 
This study showed that AAA development in Apoe
–/–
mice also affected ALI, as reflected 
by the approximately three-fold increases in BALF total inflammatory cells, macrophages, 
lymphocytes, and eosinophils (Table III in the online-only Data Supplement). AAA patients may 
bear a higher risk of developing allergic responses than AAA-free patients, a hypothesis that 
merits future investigation in a cohort of relevant patients. This study presented experimental 
mechanistic studies to establish a previously unsuspected association between ALI and AAA. 
Because allergic inflammation with altered TH2 cytokine levels and elevated plasma IgE may all 
play detrimental roles, other allergic inflammatory diseases, such as atopic dermatitis, allergic 
rhinitis, and several ocular allergic diseases might also promote AAA formation. The findings 
from this study highlight a commonality in the inflammatory pathways involved in AAA and 
other prevalent, and seemingly unrelated diseases. The results have implications for the 
development of much-needed advances in the prevention, screening criteria, and treatment of 
AAA, common conditions for which we currently lack sufficiently effective approaches.
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SIGNIFICANCE
Asthma and abdominal aortic aneurysms (AAA) both involve inflammation. Patients with 
hospital-diagnosed asthma or record of anti-asthmatic medications have a higher risk of AAA 
and aortic ruptures than those who do not, suggesting an interaction between this airway allergic 
disease and AAA. In this study, we use ovalbumin sensitization to induce allergic lung 
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inflammation (ALI) and chronic angiotensin-II infusion to produce AAA. Production of ALI 
before, after, or at the same time as AAA production greatly enlarged AAA size and increased 
lesion inflammation, along with increasing serum IgE, reducing serum Th2 cytokines, and 
increasing bronchial and alveolar inflammation. Biweekly administration of anti-IgE antibody 
depletes plasma IgE and suppresses ALI-induced AAA. Pre-establishment of AAA also 
augments bronchioalveolar inflammation. ALI also enhances peri-aortic CaCl2 injury-induced 
AAA in mice. Therefore, experimental ALI promotes AAA formation, furnishing novel links 
between airway disease and AAA and potential therapeutic strategy of human AAA.
FIGURE LEGENDS
Figure 1. Concurrent production of ALI increases AAA formation in Apoe
–/–
mice. A. Experimental 
protocol. B. Aortic diameters at harvest. C. AAA lesion macrophage and mast cell content. D. AAA 
lesion SMC loss in grade and lesion cell proliferation (Ki67) and microvascularization (microvessel 
numbers). Representative data for panels C and D are shown to the right, Scale bar: 50 µm. E. Plasma 
IgE levels. F. BALF total inflammatory cell number and eosinophil percentage. Representative 
lung histology data (H&E staining) are shown to the right, scale bar: 200 µm. 
Figure 2. OVA-induced ALI increases AAA formation in Apoe
–/–
mice. A. Experimental protocol. B.
Aortic diameters at harvest. C. AAA lesion content of macrophages and mast cells. D. AAA lesion SMC
loss in grade. Representative data for panels C and D are shown to the right, Scale bar: 50 µm. E. Plasma 
levels of IgE, IL5, IL13, and TGF-. F. BALF total inflammatory cell number and eosinophil
percentage. Representative lung histology data (H&E staining) are shown to the right, scale bar: 
200 µm. 
Figure 3. OVA-induced ALI promotes progression of pre-established AAA in Apoe
–/–
mice. A.
Experimental protocol of producing ALI alone. B. Plasma levels of IgE, IFN- and IL5. C. BALF 
total inflammatory cell number and eosinophil percentage. D. Experimental protocol of AAA 
production, followed by ALI production. E. Aortic diameters at harvest. F. AAA lesion contents of 
macrophages, CD4
+
and CD8
+
T cells, and media SMC loss in grade. G. AAA lesion numbers of Ki67-
positive proliferating cells and TUNEL-positive apoptotic cells. Representative data for panels F and G
are shown to the right, Scale bar: 50 µm. H. BALF total inflammatory cell number and eosinophil
percentage. Representative lung histology data (H&E staining) in panels C and H are shown to 
the right, scale bar: 200 µm. 
Figure 4. OVA-induced ALI promotes peri-aortic CaCl2-induced AAA in wild-type mice (panels A-G) 
and anti-IgE antibody mitigates AAA formation in mice with concurrent productions of ALI and 
Ang-II infusion-induced AAA in Apoe
–/–
mice (panels H-K). Aortic diameters from baseline and at 
harvest, and cross-section AAA lesion area (A), AAA lesion Mac-2
+
macrophage content (B), mast cell 
number (C), media SMC loss in grade (D), and CD31
+
microvessel number (E), and BALF total 
inflammatory cells and lung H&E staining from CaCl2-induced AAA mice sensitized and challenged
with OVA or saline. Plasma IgE, IL5, and IL13 (G), plasma IgE (H), aortic diameter and cross-
section AAA lesion area at harvest (I), AAA lesion Mac-2
+
macrophage content (J), and BALF total 
inflammatory cell number and lung H&E staining (K) from Apoe
–/–
mice that had Ang-II infusion-
induced AAA and sensitized and challenged with OVA or saline. Representative data for panels B, C, E,
F, J, and K are shown to the right. Scale bars: B, C-inset, E, and J: 50 µm. C, F, and K: 200 µm.
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